Literature DB >> 29311225

Keeping Tumors Out of the MAPK Fitness Zone.

David F Stern1.   

Abstract

<b/> Greatest fitness of tumor cell subclones in patients undergoing MAPK-targeting therapies requires just-right levels of MAPK pathway signaling. New therapeutic approaches induce tumor cell death by intensifying MAPK signaling induced by inhibitor withdrawal in combination with DNA damage, or prevent selection of resistant clones with a steep fitness barrier imposed by triple combination of BRAF, MEK, and ERK inhibitors. Cancer Discov; 8(1); 20-3. ©2018 AACRSee related article by Hong et al., p. 74. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29311225     DOI: 10.1158/2159-8290.CD-17-1243

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  5 in total

1.  Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities.

Authors:  Anica Dricu
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

2.  Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis.

Authors:  Jin-Wu Hu; Guang-Yu Ding; Pei-Yao Fu; Wei-Guo Tang; Qi-Man Sun; Xiao-Dong Zhu; Ying-Hao Shen; Jian Zhou; Jia Fan; Hui-Chuan Sun; Cheng Huang
Journal:  Biomed Res Int       Date:  2020-03-22       Impact factor: 3.411

Review 3.  ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer.

Authors:  Reiko Sugiura; Ryosuke Satoh; Teruaki Takasaki
Journal:  Cells       Date:  2021-09-22       Impact factor: 6.600

Review 4.  Recent advances in targeting protein kinases and pseudokinases in cancer biology.

Authors:  Kristina Riegel; Parthiban Vijayarangakannan; Petros Kechagioglou; Katarzyna Bogucka; Krishnaraj Rajalingam
Journal:  Front Cell Dev Biol       Date:  2022-07-22

Review 5.  A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer.

Authors:  Cornelia Braicu; Mihail Buse; Constantin Busuioc; Rares Drula; Diana Gulei; Lajos Raduly; Alexandru Rusu; Alexandru Irimie; Atanas G Atanasov; Ondrej Slaby; Calin Ionescu; Ioana Berindan-Neagoe
Journal:  Cancers (Basel)       Date:  2019-10-22       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.